drug
(aeruginascin + baeocystin + psilocybin)
Preclinicalupdated 6mo agoby Nova Mentis BioTech Corp
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 7- drugMYCO-0036 co-mentions · 6 sources
- drugPsilocybin (Microneedle Patch)6 co-mentions · 6 sources
- drugpsilocybin6 co-mentions · 6 sources
- drugOral Psilocybin6 co-mentions · 6 sources
- companyNew York University1 co-mentions · 1 sources
- tagPsychiatry & CNS1 co-mentions · 1 sources
- tagPain1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying (aeruginascin + baeocystin + psilocybin)
- phase2Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
- phase3Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
- phase1ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder
- phase1MLS101 Study in PMDD
- phase3The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
- phase2A Study of Psilocybin for Major Depressive Disorder (MDD)
- EP1Exploratory Study of Low Dose Psilocybin
- phase1A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
News(10)
- Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depressionHelus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious a…biospace · 2d ago
- Helus' chemically modified psychedelic hits key goals in phase 3 depression trialHelus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder.fiercebiotech · 3d ago
- HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s DayIbogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.biospace · 5d ago
- FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on OvertonIn advance of a Senate vote on Heidi Overton as the next FDA commissioner, the agency has shelved the Commissioner's National Priority Voucher program introduced by former leader Marty Makary, Reut…biospace · 6d ago
- ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veteransThe U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).fiercebiotech · 6d ago
- AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warningThe deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.biopharma_dive · 7d ago
- Update: Compass submits psilocybin depression drug for approval after stock wobblesCompass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…biospace · 9d ago
- J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionDelix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.fiercebiotech · 10d ago
- STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding billSanders could use his role in crafting the FDA funding bill to push for reforms.stat · 14d ago
- STAT+: CVS Health to split, reversing years of deal-making to combine pharmacies and insuranceCVS Health’s decision to split comes amid federal and state scrutiny over vertical integration.stat · 14d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that